SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRC, TSBX, DNOW on Behalf of Shareholders
NEW YORK, June 27, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
MRC Global Inc. (NYSE: MRC)'s sale to DNOW Inc. for 0.9489 shares of DNOW common stock for each share of MRC common stock. If you are a MRC shareholder, click here to learn more about your legal rights and options.
Turnstone Biologics Corp. (NASDAQ: TSBX)'s sale to XOMA Royalty Corporation for $0.34 in cash per share plus one non-transferable contingent value right. If you are a Turnstone shareholder, click here to learn more about your legal rights and options.
DNOW Inc. (NYSE: DNOW)'s merger with MRC Global Inc. Upon completion of the proposed transaction, DNOW shareholders will own approximately 56.5% of the combined company on a fully diluted basis. If you are a DNOW shareholder, click here to learn more about your legal rights and options.
Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-mrc-tsbx-dnow-on-behalf-of-shareholders-302493290.html
SOURCE Halper Sadeh LLP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
27 minutes ago
- Wall Street Journal
TNB Tech Minute: Trump Halts Canada Trade Talks Over New Tax on American Tech Companies - Tech News Briefing
Full Transcript This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. Victoria Craig: Here's your TNB Tech Minute for Friday, June 27th. I'm Victoria Craig for the Wall Street Journal. President Trump today terminated all trade talks with Canada, partly over a new digital services tax on American tech companies. The president said the US's northern neighbor has been, quote, a very difficult country to trade with. Trade negotiations have been taking place between the two sides for months. Meanwhile, the Trump administration is also considering executive orders aimed at increasing power generation to meet AI demand, according to people familiar with the matter. That could include giving federal land to tech companies to build data centers and expediting grid connections and permitting for advanced power generation projects. Elsewhere, in a 6-3 decision, the Supreme Court upheld a Texas law requiring certain websites that host sexual content to verify viewers' ages. The Texas law requires websites that contain more than one-third sexual material harmful to minors to use what it calls reasonable age verification methods to determine those visitors are at least 18 years old. Violations are punished with a monetary fine. Search engines and major social media networks are exempt from the state's law. And finally, New York's governor Kathy Hochul signed into law legislation requiring local governments in the state to report cyber attacks on their networks within 72 hours. It also compels organizations to report any ransom payments made to hackers within 24 hours, and mandates security awareness training for New York government employees. The state's new law is in line with pending federal regulations being hammered out by the US Cybersecurity and Infrastructure Security Agency. For a deeper dive into what's happening in tech, check out Monday's Tech News Briefing podcast.
Yahoo
34 minutes ago
- Yahoo
CFOs, investors diverge on near-term economic prospects
This story was originally published on To receive daily news and insights, subscribe to our free daily newsletter. Finance chiefs and investors appear to be at odds over the fate of the global economy in the near term. In a survey released Tuesday by New York-based consulting firm Teneo, over three-quarters of investors said they expect economic conditions to improve in the second half of 2025. That compares to just 43% of CFOs who hold the same view. Why precisely the two groups differ isn't clear; the survey didn't ask respondents to share reasons for their optimism or pessimism. But Christian Buss, co-head of investor relations at Teneo, said investors' responses show 'there could be a floor to the level of uncertainty we've seen over the last several months.' The results stem from a survey conducted May 16-29 of 132 global CFOs and 200 institutional investors. The CFO crowd and the investor crowd also held differing views on the prospect of finding capital for the remainder of the year: 68% of CFOs feel optimistic about access to capital markets versus 91% of investors. What may unite CFOs and investors is concern about the prospect of mergers and acquisitions. Teneo's survey found over 50% of CFOs and almost 40% of investors see 'market volatility as the leading barrier to deals.' Geopolitical uncertainty and the higher cost of capital were also cited among the top disruptions to deals, according to Teneo. Across the board, respondents also said they're optimistic about debt market access (81% of CFOs and 89% of investors) and the impact of private equity (70% of CFOs and 87% of investors). Among the CFO respondents, there was also a notable difference in sentiment by geography. Fifty-three percent of U.S.-based finance chiefs expect economic improvement in the latter half of the year compared to just 29% of international CFOs. Buss said the 'relative bearishness of global CFOs' is worth noting. 'It's a clear sign that changes to the global trade environment we all have been grappling with over the last two months are having wide-ranging impacts across economies and industries,' Buss said. More than half of CFO respondents (55%) were based in the U.S. On the investor side, just 27% were based in the U.S. For their part, CFOs said they're already making adjustments to their operations in light of 'economic headwinds, including tariffs,' per the report. 'CFOs are re-examining the location of manufacturing hubs globally, with a full 86% saying they are actively reshaping global supply chains, while also reconsidering CapEx and general corporate spending,' wrote Teneo CEO Paul Keary in the report's introduction. Teneo has been issuing similar surveys of CEOs in the past, but this week's report marks the first for finance chiefs. In the report, Keary said the new report came at the request of respondents in prior surveys: 'Given the rapid pace of change around the world, respondents suggested that we also mine the views of CFOs, given their key role in capital allocation and financial strategy.' Recommended Reading CFOs slash profit forecasts by 22% as economy triggers concern Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
AI in drug discovery: from hypothetical to reality
AI has been a buzzword in the pharmaceutical industry for almost a decade, with countless headlines promising to revolutionise how drugs are discovered, developed, and deployed. The hype has typically outpaced reality; however, with a growing number of AI-generated drug candidates entering clinical trials, we find ourselves at a crucial potential turning point for the field. As the first AI-designed molecules begin clinical trials, the industry is watching closely to see if AI can deliver novel, successful therapies or if it will remain a supporting tool in an already complex research process. AI is not a single technology, but a broad set of computational tools that can support nearly every stage of drug development. In early discovery, AI can help identify novel targets, generate new chemical compounds, predict how drugs will interact with proteins, and optimise lead compounds (promising compounds that show potential as an effective drug) for desirable properties. In later stages, it is increasingly used to select patients for clinical trials, repurpose existing drugs, and predict adverse effects. Early attention focused on the ability of generative AI models, particularly deep learning and reinforcement learning frameworks, to create candidate compounds faster than any human chemist, with a theoretical ability to explore vast chemical spaces more efficiently than traditional methods. AI-designed candidates used to remain confined to in silico (computational) experiments or the preclinical stage. That is now changing. In the past two years, several AI-designed drugs have advanced into human trials, providing the first real-world test of these technologies in the clinic. Insilico Medicine, a Hong Kong- and New York-based AI biotech company, gained attention in 2023 when it announced that its drug candidate INS018_055, developed using its proprietary platform, had entered Phase II trials (testing effectiveness and safety). The compound was designed from scratch using generative models trained on structural data, an early confirmation that AI can do more than just screen libraries. Other companies such as BenevolentAI, Recursion, Schrödinger, and Relay Therapeutics are advancing candidates identified, optimised, or prioritised using AI tools, though not all are strictly 'AI-generated'. Importantly, these companies are not just discovering molecules but also positioning themselves as drug developers and strategic collaborators. Big pharma has increasingly embraced AI, using partnerships, joint ventures, and acquisitions to reduce risk in target selection and accelerate early-stage drug development. A prime example is this deal between Sanofi and Exscientia, worth up to $5.2bn, focused on AI-designed small molecules across oncology and immunology. Furthermore, AstraZeneca has been collaborating with BenevolentAI to identify new drug targets in chronic kidney disease and fibrosis. Pfizer, Bayer, Merck, and Roche have all partnered with AI-native biotechs or built their own internal capabilities, often focused on areas such as rare diseases, central nervous system disorders, or target deconvolution. These collaborations reflect a broader shift in mindset: AI is increasingly seen not as a competitor to traditional research and development (R&D), but as a strategic enabler, using human expertise to improve accuracy and compress timelines in high-risk areas. The core value proposition of AI in drug discovery is speed and efficiency. Drug development typically costs over $2bn and can take 10-15 years per new drug. AI promises to shorten the time from target identification to candidate nomination by rapidly generating hit compounds, improving target-disease linkage accuracy, and selecting better patient populations for trials. Insilico, for example, claimed that INS018_055 progressed from target discovery to Investigational New Drug filing in under 30 months, significantly faster than industry averages. However, real-world validation of these efficiency claims is still pending, and it remains unclear whether AI shortens timelines in later-stage development, where most costs and failures still occur. Moreover, regulatory pathways for AI-designed drugs are still evolving. While the molecules themselves follow industry standards, questions remain around intellectual property ownership, algorithm transparency, and validation of model-generated hypotheses. The excitement around AI in drug discovery has driven enormous investor interest, bringing volatility along with it. Many AI-first biotech companies raised substantial capital through initial public offerings or special-purpose acquisition companies (SPACs) deals during the 2021-22 biotech boom. Yet several have seen share prices decline sharply as investor enthusiasm met the realities of long development timelines, modest clinical progress, and uncertain monetisation strategies. BenevolentAI, for example, went public via a €1.5bn ($1.8bn) SPAC in 2022 but lost over 70% of its value by mid-2024. Recursion, despite its ambitious data-driven drug discovery platform and partnerships with Bayer and Roche, has also faced pressure from shareholders seeking faster returns. Despite this, the field is still maturing. Investors and pharma partners are shifting from broad platforms to more focused evaluations based on data-driven productivity, clinical progress, and pipeline value. The industry is now approaching a key milestone: the first regulatory approval of an AI-designed drug. If INS018_055 delivers positive Phase II data, it would mark a transformative moment, validating AI not just as a tool but as a source of new and unique therapies. Looking further ahead, AI could diversify drug development by enabling smaller companies to design high-quality molecules without vast lab infrastructure. It may also unlock progress in rare diseases, neglected indications, or emerging pathogens, where traditional business models struggle to justify investment. Beyond small molecules, AI is also being explored in biologics design, protein engineering, messenger ribonucleic acid optimisation, and clinical trial design, suggesting its impact could extend across the entire pharmaceutical value chain. AI is no longer just a futuristic concept in pharma; it is producing real assets, forming strategic alliances, and slowly earning its place in the clinical pipeline. However, expectations remain high, and the burden of proof now rests on human trials, not machine models. As the first wave of AI-designed drugs enters mid-stage development, the industry will be watching not just for approvals, but for evidence that AI can improve outcomes, accelerate timelines, and reduce costs in a field where failure is still the norm. If successful, the next decade may not just belong to AI, it may be designed by it. "AI in drug discovery: from hypothetical to reality" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
